Literature DB >> 14688334

CXCR1+CD4+ T cells in human allergic disease.

James N Francis1, Mikila R Jacobson, Clare M Lloyd, Ian Sabroe, Stephen R Durham, Stephen J Till.   

Abstract

Chemokine receptors play an important role in the migration of leukocytes to sites of allergic inflammation in humans. In this study, we have identified increased expression of the chemokine receptor CXCR1 on CD4+ T lymphocytes derived from patients with atopic disease compared with normal donors. Enhanced expression of CXCR1 by atopic donors was identified on freshly isolated peripheral blood cells and on expanded cell populations derived from nasal mucosal biopsies and from the periphery. Identification of CXCR1 expression on CD4 cells in the nasal mucosa was confirmed by double immunofluorescence. In addition, expression of CXCR1 was dramatically decreased in patients undergoing successful treatment of allergic rhinitis by specific immunotherapy. CXCR1 provided a functional receptor capable of regulating T cells in the context of allergic disease, since expression of CXC chemokine ligand 8 was up-regulated at the site of allergic inflammation and freshly isolated CXCR1+CD4+ cells from atopic donors showed an enhanced functional response to this ligand. CXCR1 expression on CD4+ T cells was increased in vitro in response to the pro-Th2 cytokine IL-4. Phenotypic analysis reveals that IFN-gamma expression was lower in the CXCR1+CD4+ cells. The identification of CXCR1 as a marker of allergic rhinitis reveals a possible target for therapeutic intervention in atopic disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688334     DOI: 10.4049/jimmunol.172.1.268

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood.

Authors:  Adnan Custovic; Lars Soderstrom; Staffan Ahlstedt; Peter D Sly; Angela Simpson; Patrick G Holt
Journal:  J Allergy Clin Immunol       Date:  2011-04-13       Impact factor: 10.793

Review 2.  Chemokines and their receptors in the allergic airway inflammatory process.

Authors:  Juan Raymundo Velazquez; Luis Manuel Teran
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

3.  A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa.

Authors:  E Danilova; I Skrindo; E Gran; B J Hales; W A Smith; J Jahnsen; F E Johansen; F L Jahnsen; E S Baekkevold
Journal:  Mucosal Immunol       Date:  2014-06-11       Impact factor: 7.313

4.  Elevated CCR6+ CD4+ T lymphocytes in tissue compared with blood and induction of CCL20 during the asthmatic late response.

Authors:  J N Francis; I Sabroe; C M Lloyd; S R Durham; S J Till
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

5.  Chemokine responsiveness of CD4+ CD25+ regulatory and CD4+ CD25- T cells from atopic and nonatopic donors.

Authors:  D Ahern; C M Lloyd; D S Robinson
Journal:  Allergy       Date:  2009-02-07       Impact factor: 13.146

6.  T lymphocytes expressing CCR3 are increased in allergic rhinitis compared with non-allergic controls and following allergen immunotherapy.

Authors:  J N Francis; C M Lloyd; I Sabroe; S R Durham; S J Till
Journal:  Allergy       Date:  2007-01       Impact factor: 13.146

Review 7.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.